IXICO plc (IXI.L) LSE

12.25

-0.099(-0.81%)

Updated at August 18 04:35PM

Currency In GBp

IXICO plc

Address

Griffin Court

London, EC1A 9PN

United Kingdom of Great Britain and Northern Ireland

Phone

44 20 3763 7499

Sector

Healthcare

Industry

Biotechnology

Employees

81

First IPO Date

April 25, 1996

Key Executives

NameTitlePayYear Born
Mr. Bram Goorden M.Sc.Chief Executive Officer & Director339,2691973
Mr. Grant Robert NashChief Financial Officer, Company Secretary & Executive Director221,0001976
Prof. Derek Lionel Glendon Hill Ph.D.Co-Founder and President of Regulatory Science & External Relations387,0061966
Prof. Daniel RueckertCo-Founder & Member of Scientific Advisory Board0N/A
Dr. Robin WolzChief Scientific Officer0N/A
Prof. David Hawkes CPhys, FInstP, FIPEM, FREng, Ph.D.Co-Founder & Member of Scientific Advisory Board0N/A
Mr. Lammert AlbersChief Business Officer0N/A
Prof. Joseph HajnalCo-Founder & Member of Scientific Advisory Board0N/A
Dr. John HallSenior Vice President of Business Development01979
Ms. Hannah EsfahanianHR Manager0N/A

Description

IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. Its focused therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. The company also engages in the data collection, optimization, and analytics of rare neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.